Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3′,5′—monophosphate phosphodiesterase (cGMP PDE5) for the treatment of sexual dysfunction

Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3′,5′—monophosphate phosphodiesterase (cGMP PDE5) for the treatment of sexual dysfunction

US Patent 6723719 · Granted Apr 20, 2004

Estimated economic value: $379,600,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Bicyclic-fused heteroaryl or aryl compounds2025
Bicyclic-fused heteroaryl or aryl compounds2025
Bicyclic-fused heteroaryl or aryl compounds2023
Bicyclic-fused heteroaryl or aryl compounds2023
Bicyclic-fused heteroaryl or aryl compounds2020
Bicyclic-fused heteroaryl or aryl compounds2020
Bicyclic heteroaryl derivatives as CFTR potentiators2020
Pyrrolopyrimidines as CFTR potentiators2019
Bicyclic heteroaryl derivatives as CFTR potentiators2019
Bicyclic-fused heteroaryl or aryl compounds2019
Bicyclic-fused heteroaryl or aryl compounds2019
Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators2019